中国医药制造市场蓬勃发展,CPhI China助力企业走向新格局

2017-12-01 佚名 MedSci原创

上海2017年11月30日电 /美通社/ -- 随着全球经济一体化、中国药品走向世界的步伐加快,目前中国已成为全球第二大医药消费市场、第一大原料药出口国。中国现有近5000家原料和制剂企业,医药制造业年度主营业务收入超过2.5万亿元人民币,其中有近50家制剂企业通过欧美的认证或检查,医药制造品出口额超过135亿美元,骄人的业绩,证明了中国医药产业已经具备为世界其他国家提供安全可靠医药产品的能力。

在此背景下,由欧洲博闻展览咨询有限公司(UBM EMEA)和中国医药保健品进出口商会(CCCMHPIE)主办、上海博华国际展览有限公司(UBM Sinoexpo)协办的“第十八届世界制药原料中国展”暨“第十三届世界制药机械、包装设备与材料中国展”(CPhI & P-MEC China 2018)将于2018年6月20-22日在上海新国际博览中心隆重召开,伴随中国医药市场的蓬勃发展,CPhI China将助力企业乘此医药新风,开拓国际化市场新格局。

展会现场人气爆棚
展会现场人气爆棚

延伸产业链,打造上下游一体化平台

自2001 年引入中国的十七年间,CPhI China 在深入扎根制药原料产业的同时顺应行业发展趋势,不断开拓延伸上下游产业链,目前已囊括包括P-MEC 制药机械板块在内的共13大版块,成为全球首屈一指的制药行业垂直产业链专业贸易交流盛会。其中,CPhI China药用辅料专区经过5年的发展,将在2018年升级成为独立展会 -- “国际药用辅料与技术中国展”(PharmaExcipients China),届时百余家国内外知名药用辅料生产企业将齐聚一堂,展示其创新产品及技术,助力行业新剂型和新制剂的开发,让国内医药企业走上更具竞争力的创新型道路。除此之外,主办方也在不遗余力的进一步挖掘上下游行业潜力。2018展会将在W5馆开辟全新“兽药及饲料”专区,展品范围涵盖饲料原料及添加剂、兽用生物制品、兽用诊断试剂、兽用原料药、兽药制剂、动物保健品等,拓展行业产业链,进一步促进人类和动物的共同健康。

展商展位热烈洽谈
展商展位热烈洽谈

网络全球资源,更多海外展团入驻

CPhI & P-MEC China 2018年展会面积将扩展至170,000平方米,预计将汇聚3,000余家国内外优秀的企业,吸引来自120个国家与地区60,000余人次海内外专业观众,现场还将举办80余场精彩的会议活动,呈现全球制药最新发展趋势与先进技术。CPhI & P-MEC China素来以国际化程度高著称, 2018年展会上除了原有的韩国、印度展团外,还将在E1馆海外区增设巴西展团,让展会的国际化程度迈上崭新台阶。同时,观众的国际化程度也在逐年攀升,2017年展会现场,CPhI & P-MEC China联袂同期FiAC食品系列展会吸引共计12,582人次海外观众,令展商赞不绝口。浙江海翔药业股份有限公司副总裁许国睿表示:“我们从2001年开始每年都参加CPhI上海展会,通过这个平台,展示了企业形象,结识了很多重要客户,开展了深度合作,把我们的企业和产品推向全球市场,CPhI是我们国际化战略的重要窗口。”

海外专业买家齐聚
海外专业买家齐聚

China Pharma Week再次启动,行业高端社交盛宴不容错过

作为始终走在国际制药行业前沿的展会,CPhI China在2018年展会同期将继续推出“China Pharma Week”主题活动周(6月19-23日),涵盖制药行业Leadership、Business、Networking、Recognition、Knowledge、Innovation六大主题。会议内容覆盖面广,包含国内外医药法规新政解析、最新专利和知识产权等方面的解读、绿色工艺改造展示等,活动形式多样,从重量级的行业评选、针对职场女性的沙龙,到工厂参观、企业高层交流晚宴等,打造集贸易、社交、知识分享为一体的年度高端制药行业盛会。

获悉全球药政-CPhI 国际药政答疑会
获悉全球药政-CPhI 国际药政答疑会

2018展位预订已经过半,各大企业接踵而至。即刻访问展会官网www.cphi-china.cn或关注微信订阅号CPhI-China在线报名参展,加入年度制药盛会,共襄制药人的行业盛举

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2079764, encodeId=ff0c20e97642a, content=<a href='/topic/show?id=0e9421e61cb' target=_blank style='color:#2F92EE;'>#中国医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21761, encryptionId=0e9421e61cb, topicName=中国医药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=zhangpaul93, createdTime=Sat May 19 04:24:00 CST 2018, time=2018-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2008123, encodeId=a487200812371, content=<a href='/topic/show?id=f244465139' target=_blank style='color:#2F92EE;'>#CHINA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4651, encryptionId=f244465139, topicName=CHINA)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Tue Dec 05 13:24:00 CST 2017, time=2017-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409215, encodeId=f282140921541, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Sun Dec 03 00:24:00 CST 2017, time=2017-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1456140, encodeId=1bd41456140de, content=<a href='/topic/show?id=3cdb2563088' target=_blank style='color:#2F92EE;'>#企业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25630, encryptionId=3cdb2563088, topicName=企业)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a765759005, createdName=hyf030, createdTime=Sun Dec 03 00:24:00 CST 2017, time=2017-12-03, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2079764, encodeId=ff0c20e97642a, content=<a href='/topic/show?id=0e9421e61cb' target=_blank style='color:#2F92EE;'>#中国医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21761, encryptionId=0e9421e61cb, topicName=中国医药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=zhangpaul93, createdTime=Sat May 19 04:24:00 CST 2018, time=2018-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2008123, encodeId=a487200812371, content=<a href='/topic/show?id=f244465139' target=_blank style='color:#2F92EE;'>#CHINA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4651, encryptionId=f244465139, topicName=CHINA)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Tue Dec 05 13:24:00 CST 2017, time=2017-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409215, encodeId=f282140921541, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Sun Dec 03 00:24:00 CST 2017, time=2017-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1456140, encodeId=1bd41456140de, content=<a href='/topic/show?id=3cdb2563088' target=_blank style='color:#2F92EE;'>#企业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25630, encryptionId=3cdb2563088, topicName=企业)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a765759005, createdName=hyf030, createdTime=Sun Dec 03 00:24:00 CST 2017, time=2017-12-03, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2079764, encodeId=ff0c20e97642a, content=<a href='/topic/show?id=0e9421e61cb' target=_blank style='color:#2F92EE;'>#中国医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21761, encryptionId=0e9421e61cb, topicName=中国医药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=zhangpaul93, createdTime=Sat May 19 04:24:00 CST 2018, time=2018-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2008123, encodeId=a487200812371, content=<a href='/topic/show?id=f244465139' target=_blank style='color:#2F92EE;'>#CHINA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4651, encryptionId=f244465139, topicName=CHINA)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Tue Dec 05 13:24:00 CST 2017, time=2017-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409215, encodeId=f282140921541, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Sun Dec 03 00:24:00 CST 2017, time=2017-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1456140, encodeId=1bd41456140de, content=<a href='/topic/show?id=3cdb2563088' target=_blank style='color:#2F92EE;'>#企业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25630, encryptionId=3cdb2563088, topicName=企业)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a765759005, createdName=hyf030, createdTime=Sun Dec 03 00:24:00 CST 2017, time=2017-12-03, status=1, ipAttribution=)]
    2017-12-03 cathymary
  4. [GetPortalCommentsPageByObjectIdResponse(id=2079764, encodeId=ff0c20e97642a, content=<a href='/topic/show?id=0e9421e61cb' target=_blank style='color:#2F92EE;'>#中国医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21761, encryptionId=0e9421e61cb, topicName=中国医药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=zhangpaul93, createdTime=Sat May 19 04:24:00 CST 2018, time=2018-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2008123, encodeId=a487200812371, content=<a href='/topic/show?id=f244465139' target=_blank style='color:#2F92EE;'>#CHINA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4651, encryptionId=f244465139, topicName=CHINA)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Tue Dec 05 13:24:00 CST 2017, time=2017-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409215, encodeId=f282140921541, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Sun Dec 03 00:24:00 CST 2017, time=2017-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1456140, encodeId=1bd41456140de, content=<a href='/topic/show?id=3cdb2563088' target=_blank style='color:#2F92EE;'>#企业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25630, encryptionId=3cdb2563088, topicName=企业)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a765759005, createdName=hyf030, createdTime=Sun Dec 03 00:24:00 CST 2017, time=2017-12-03, status=1, ipAttribution=)]
    2017-12-03 hyf030

相关资讯

英国国家卫生与保健评价研究院发布新的哮喘指南

/* Style Definitions */ span.prnews_span { font-size:8pt; font-family:"Arial"; color:black; } a.prnews_a { color:blue; } li.prnews_li

春雨医生再获国际认可 获评亚太地区“数字化转型颠覆者”

/* Style Definitions */ span.prnews_span { font-size:8pt; font-family:"Arial"; color:black; } a.prnews_a { color:blue; } li.prnews_li